Pirfenidone

Identification

Name
Pirfenidone
Accession Number
DB04951
Type
Small Molecule
Groups
Approved, Investigational
Description

Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It is being investigated by InterMune.

Structure
Thumb
Synonyms
Not Available
External IDs
AMR-69
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EsbrietTablet267 mgOralHoffmann La Roche2017-07-26Not applicableCanada
EsbrietCapsule267 mg/1OralInter Mune2014-10-16Not applicableUs
EsbrietCapsule267 mgOralRoche Registration Limited2011-02-28Not applicableEu
EsbrietTablet, coated267 mg/1OralGenentech, Inc.2017-01-11Not applicableUs
EsbrietTablet801 mgOralHoffmann La Roche2017-07-26Not applicableCanada
EsbrietCapsule267 mgOralHoffmann La Roche2013-01-08Not applicableCanada
EsbrietCapsule267 mgOralRoche Registration Limited2011-02-28Not applicableEu
EsbrietTablet, coated801 mg/1OralGenentech, Inc.2017-01-11Not applicableUs
EsbrietCapsule267 mgOralRoche Registration Limited2011-02-28Not applicableEu
EsbrietCapsule267 mg/1OralGenentech, Inc.2014-10-16Not applicableUs
Categories
UNII
D7NLD2JX7U
CAS number
53179-13-8
Weight
Average: 185.2218
Monoisotopic: 185.084063979
Chemical Formula
C12H11NO
InChI Key
ISWRGOKTTBVCFA-UHFFFAOYSA-N
InChI
InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3
IUPAC Name
5-methyl-1-phenyl-1,2-dihydropyridin-2-one
SMILES
CC1=CN(C(=O)C=C1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of idiopathic pulmonary fibrosis (IPF).

Structured Indications
Not Available
Pharmacodynamics

Pirfenidone is a novel agent with anti-inflammatory, antioxidant, and antifibrotic properties. It may improve lung function and reduce the number of acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF).

Mechanism of action

Pirfenidone is an orally active, small molecule that shows a wide range of biologic activity. In vitro evidence has shown that pirfenidone inhibits collagen synthesis, down-regulates profibrotic cytokines and decreases fibroblast proliferation. Pirfenidone leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin. In addition, pirfenidone reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-beta target gene and furin substrate involved in carcinogenesis.

TargetActionsOrganism
UFurinNot AvailableHuman
Absorption

Rapidly absorbed following oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

2-2.5 hours

Clearance
Not Available
Toxicity

Generally well tolerated with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with 5-androstenedione.Experimental, Illicit
AbataceptThe risk or severity of infection can be increased when Pirfenidone is combined with Abatacept.Approved
AbciximabPirfenidone may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Pirfenidone can be increased when it is combined with Abiraterone.Approved
AcebutololPirfenidone may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Acemetacin.Approved
AcenocoumarolPirfenidone may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pirfenidone.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Pirfenidone.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Pirfenidone.Approved, Vet Approved
AclarubicinPirfenidone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Pirfenidone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Alendronic acid.Approved
AliskirenPirfenidone may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Alminoprofen.Experimental
AlprenololPirfenidone may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Pirfenidone.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Amcinonide.Approved
AmikacinPirfenidone may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmiloridePirfenidone may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinPirfenidone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnakinraThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Anakinra.Approved
AncrodPirfenidone may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Anisodamine.Investigational
annamycinPirfenidone may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Pirfenidone.Approved
Antithrombin III humanPirfenidone may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanPirfenidone may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Apocynin.Investigational
ApramycinPirfenidone may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Apremilast.Approved, Investigational
ArbekacinPirfenidone may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinPirfenidone may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanPirfenidone may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololPirfenidone may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Atamestane.Investigational
AtenololPirfenidone may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Pirfenidone.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Pirfenidone.Approved
AzithromycinThe serum concentration of Pirfenidone can be increased when it is combined with Azithromycin.Approved
BalsalazidePirfenidone may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Pirfenidone.Investigational
BecaplerminPirfenidone may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololPirfenidone may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinPirfenidone may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Pirfenidone.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Pirfenidone.Approved
BenorilateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Pirfenidone.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Pirfenidone.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Betamethasone.Approved, Vet Approved
BetaxololPirfenidone may decrease the antihypertensive activities of Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Pirfenidone.Approved, Investigational
BevantololPirfenidone may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Pirfenidone.Approved, Investigational
BisoprololPirfenidone may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinPirfenidone may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololPirfenidone may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe serum concentration of Pirfenidone can be increased when it is combined with Bortezomib.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pirfenidone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Bucillamine.Investigational
BucindololPirfenidone may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Bufexamac.Experimental
BufuralolPirfenidone may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Bumadizone.Experimental
BumetanidePirfenidone may decrease the diuretic activities of Bumetanide.Approved
BupranololPirfenidone may decrease the antihypertensive activities of Bupranolol.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pirfenidone.Approved
CaffeineThe serum concentration of Pirfenidone can be increased when it is combined with Caffeine.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Canakinumab.Approved, Investigational
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Pirfenidone.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Pirfenidone.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pirfenidone.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Pirfenidone.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Pirfenidone.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Pirfenidone.Approved, Vet Approved, Withdrawn
CarteololPirfenidone may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolPirfenidone may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Pirfenidone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Pirfenidone.Approved, Investigational
CeliprololPirfenidone may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
Certolizumab pegolPirfenidone may increase the immunosuppressive activities of Certolizumab pegol.Approved
CertoparinPirfenidone may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Pirfenidone.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pirfenidone.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Pirfenidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Pirfenidone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Pirfenidone.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pirfenidone.Approved
CinoxacinPirfenidone may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe serum concentration of Pirfenidone can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Pirfenidone can be increased when it is combined with Citalopram.Approved
Citric AcidPirfenidone may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Pirfenidone.Vet Approved
CloranololPirfenidone may decrease the antihypertensive activities of Cloranolol.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pirfenidone.Approved
ClotrimazoleThe serum concentration of Pirfenidone can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Pirfenidone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Pirfenidone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Cortisone acetate.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pirfenidone.Approved
CurcuminThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Pirfenidone.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Pirfenidone.Approved, Investigational
CyclosporinePirfenidone may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Pirfenidone.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with D-Limonene.Investigational
Dabigatran etexilatePirfenidone may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinPirfenidone may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidPirfenidone may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanPirfenidone may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinPirfenidone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Deflazacort.Approved
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Pirfenidone.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Pirfenidone.Approved
DesirudinPirfenidone may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pirfenidone.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Pirfenidone.Approved, Investigational
DextranPirfenidone may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Pirfenidone may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Pirfenidone may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Pirfenidone may increase the anticoagulant activities of Dextran 75.Approved
DibekacinPirfenidone may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Pirfenidone.Approved, Vet Approved
DicoumarolPirfenidone may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pirfenidone.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pirfenidone.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Pirfenidone.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pirfenidone.Approved
DihydrostreptomycinPirfenidone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Pirfenidone.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Pirfenidone.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Pirfenidone.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirfenidone.Approved, Investigational
DosulepinThe serum concentration of Pirfenidone can be increased when it is combined with Dosulepin.Approved
DoxorubicinPirfenidone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenonePirfenidone may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Pirfenidone is combined with E-6201.Investigational
Edetic AcidPirfenidone may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanPirfenidone may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Pirfenidone.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pirfenidone.Approved
EnoxacinPirfenidone may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinPirfenidone may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Pirfenidone.Experimental
EpanololPirfenidone may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Epirizole.Approved
EpirubicinPirfenidone may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenonePirfenidone may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Pirfenidone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pirfenidone.Approved
EquileninThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Equilin.Approved
EsmololPirfenidone may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Estrone sulfate.Approved
Etacrynic acidPirfenidone may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Pirfenidone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Ethenzamide.Experimental
Ethyl biscoumacetatePirfenidone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Pirfenidone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Pirfenidone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Pirfenidone is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Pirfenidone.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Pirfenidone.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Feprazone.Experimental
Ferulic acidPirfenidone may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Pirfenidone.Approved, Investigational
FingolimodPirfenidone may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinPirfenidone may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Pirfenidone.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fludrocortisone.Approved
FluindionePirfenidone may increase the anticoagulant activities of Fluindione.Investigational
FlumequinePirfenidone may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Pirfenidone.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pirfenidone.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluticasone propionate.Approved
FluvoxamineThe serum concentration of Pirfenidone can be increased when it is combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Pirfenidone.Approved, Nutraceutical, Vet Approved
FondaparinuxPirfenidone may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumPirfenidone may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Pirfenidone.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pirfenidone.Approved
FramycetinPirfenidone may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemidePirfenidone may decrease the diuretic activities of Furosemide.Approved, Vet Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Pirfenidone.Investigational
GabexatePirfenidone may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinPirfenidone may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinPirfenidone may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Pirfenidone.Approved, Withdrawn
GemifloxacinPirfenidone may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinPirfenidone may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinPirfenidone may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1APirfenidone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Pirfenidone.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Pirfenidone.Experimental
GPX-150Pirfenidone may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinPirfenidone may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Pirfenidone is combined with HE3286.Investigational
HeparinPirfenidone may increase the anticoagulant activities of Heparin.Approved, Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pirfenidone.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pirfenidone.Approved, Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Higenamine.Investigational
HydralazinePirfenidone may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Pirfenidone.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Pirfenidone.Approved, Investigational
Hygromycin BPirfenidone may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Pirfenidone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Icatibant.Approved
IdarubicinPirfenidone may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxPirfenidone may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Pirfenidone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Pirfenidone.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Pirfenidone.Approved
IndenololPirfenidone may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pirfenidone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Indoprofen.Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Pirfenidone.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Pirfenidone.Investigational
INNO-206Pirfenidone may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pirfenidone.Approved, Investigational
IsepamicinPirfenidone may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Istaroxime.Investigational
KanamycinPirfenidone may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Pirfenidone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pirfenidone.Approved
LabetalolPirfenidone may decrease the antihypertensive activities of Labetalol.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Pirfenidone.Experimental
LandiololPirfenidone may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Pirfenidone.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Pirfenidone.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Leflunomide.Approved, Investigational
LepirudinPirfenidone may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanPirfenidone may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololPirfenidone may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinPirfenidone may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LidocaineThe serum concentration of Pirfenidone can be increased when it is combined with Lidocaine.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Pirfenidone.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pirfenidone.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Pirfenidone.Approved
LobeglitazoneThe serum concentration of Pirfenidone can be increased when it is combined with Lobeglitazone.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Pirfenidone.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Pirfenidone.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Pirfenidone.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Pirfenidone.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pirfenidone.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pirfenidone.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Pirfenidone is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pirfenidone.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pirfenidone.Approved
MelagatranPirfenidone may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Pirfenidone.Approved, Vet Approved
MepindololPirfenidone may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazinePirfenidone may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Pirfenidone.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Pirfenidone.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pirfenidone.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Pirfenidone.Experimental
MetipranololPirfenidone may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Pirfenidone.Approved
MetoprololPirfenidone may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamidePirfenidone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MexiletineThe serum concentration of Pirfenidone can be increased when it is combined with Mexiletine.Approved
MicronomicinPirfenidone may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe serum concentration of Pirfenidone can be increased when it is combined with Midostaurin.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Pirfenidone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Pirfenidone.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Pirfenidone.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pirfenidone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pirfenidone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Pirfenidone.Approved
NadololPirfenidone may decrease the antihypertensive activities of Nadolol.Approved
NadroparinPirfenidone may increase the anticoagulant activities of Nadroparin.Approved
NafamostatPirfenidone may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Pirfenidone.Approved
Nalidixic AcidPirfenidone may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Pirfenidone.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Pirfenidone is combined with NCX 1022.Investigational
NeaminePirfenidone may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololPirfenidone may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinPirfenidone may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinPirfenidone may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Pirfenidone.Approved
NetilmicinPirfenidone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NevirapineThe serum concentration of Pirfenidone can be increased when it is combined with Nevirapine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pirfenidone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pirfenidone.Approved, Investigational, Withdrawn
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Pirfenidone.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Nitroaspirin.Investigational
NorfloxacinPirfenidone may increase the neuroexcitatory activities of Norfloxacin.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Pirfenidone.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pirfenidone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pirfenidone.Approved
OlsalazinePirfenidone may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Pirfenidone.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Orgotein.Vet Approved
OtamixabanPirfenidone may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Pirfenidone.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pirfenidone.Approved
Oxolinic acidPirfenidone may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololPirfenidone may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pirfenidone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pirfenidone.Approved, Vet Approved
PamidronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Parecoxib.Approved
ParomomycinPirfenidone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Parthenolide.Investigational
PazufloxacinPirfenidone may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinPirfenidone may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololPirfenidone may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitratePirfenidone may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfatePirfenidone may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Pirfenidone.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Pirfenidone.Experimental
PhenindionePirfenidone may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonPirfenidone may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pirfenidone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pirfenidone.Approved, Investigational
PindololPirfenidone may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidPirfenidone may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinPirfenidone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanidePirfenidone may decrease the diuretic activities of Piretanide.Experimental
Piromidic acidPirfenidone may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pirfenidone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Pirprofen.Experimental
Platelet Activating FactorPirfenidone may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinPirfenidone may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinPirfenidone may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Pirfenidone.Approved
PractololPirfenidone may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Pirfenidone.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Pirfenidone can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Propacetamol.Approved, Investigational
PropranololPirfenidone may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Proquazone.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Pirfenidone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Pirfenidone.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Pirfenidone.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Pirfenidone.Vet Approved
Protein CPirfenidone may increase the anticoagulant activities of Protein C.Approved
Protein S humanPirfenidone may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePirfenidone may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinPirfenidone may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Pirfenidone is combined with PTC299.Investigational
PuromycinPirfenidone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Pirfenidone.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Pirfenidone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pirfenidone.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Pirfenidone.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pirfenidone.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pirfenidone.Approved, Experimental, Investigational
ReviparinPirfenidone may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinPirfenidone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Rilonacept.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Rimexolone.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Pirfenidone.Investigational
RisedronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Risedronate.Approved, Investigational
RivaroxabanPirfenidone may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Pirfenidone.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Pirfenidone.Approved
RopiniroleThe serum concentration of Pirfenidone can be increased when it is combined with Ropinirole.Approved, Investigational
RosoxacinPirfenidone may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Pirfenidone.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Pirfenidone.Approved
RufloxacinPirfenidone may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinPirfenidone may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Pirfenidone.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Pirfenidone.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Pirfenidone.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Pirfenidone.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Pirfenidone.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Pirfenidone.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Serrapeptase.Investigational
SimeprevirThe serum concentration of Pirfenidone can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pirfenidone.Approved
SisomicinPirfenidone may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinPirfenidone may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Pirfenidone.Approved
SotalolPirfenidone may decrease the antihypertensive activities of Sotalol.Approved
SP1049CPirfenidone may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinPirfenidone may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinPirfenidone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Pirfenidone.Approved
SpironolactonePirfenidone may decrease the antihypertensive activities of Spironolactone.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Pirfenidone.Investigational
SRT501The risk or severity of adverse effects can be increased when Pirfenidone is combined with SRT501.Investigational
StreptomycinPirfenidone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinPirfenidone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pirfenidone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Pirfenidone.Approved
SulodexidePirfenidone may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Pirfenidone.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Pirfenidone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Suxibuzone.Experimental
TacrolimusPirfenidone may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Pirfenidone.Approved
TalinololPirfenidone may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Pirfenidone.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Pirfenidone.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Pirfenidone.Investigational
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pirfenidone.Approved, Investigational
TemafloxacinPirfenidone may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Pirfenidone.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Pirfenidone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Teriflunomide.Approved
TertatololPirfenidone may decrease the antihypertensive activities of Tertatolol.Experimental
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Pirfenidone.Investigational
TheophyllineThe serum concentration of Pirfenidone can be increased when it is combined with Theophylline.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pirfenidone.Approved
TiclopidineThe serum concentration of Pirfenidone can be increased when it is combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololPirfenidone may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tixocortol.Approved
TobramycinPirfenidone may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabTocilizumab may increase the immunosuppressive activities of Pirfenidone.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pirfenidone.Approved
TorasemidePirfenidone may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pirfenidone.Approved
TranilastThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Pirfenidone.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Pirfenidone.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Pirfenidone.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Triamcinolone.Approved, Vet Approved
TriamterenePirfenidone may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Pirfenidone.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Triptolide.Investigational
TrovafloxacinPirfenidone may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinPirfenidone may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Pirfenidone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Pirfenidone.Investigational, Withdrawn
ValrubicinPirfenidone may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Pirfenidone.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Pirfenidone.Approved
VedolizumabThe risk or severity of infection can be increased when Pirfenidone is combined with Vedolizumab.Approved
WarfarinPirfenidone may increase the anticoagulant activities of Warfarin.Approved
XimelagatranPirfenidone may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Pirfenidone.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Pirfenidone.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Pirfenidone.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pirfenidone.Withdrawn
Zoptarelin doxorubicinPirfenidone may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinPirfenidone may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Pirfenidone.Approved
ZucapsaicinThe serum concentration of Pirfenidone can be increased when it is combined with Zucapsaicin.Approved
Food Interactions
Not Available

References

General References
  1. Hale ML, Margolin SB, Krakauer T, Roy CJ, Stiles BG: Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. Infect Immun. 2002 Jun;70(6):2989-94. [PubMed:12010989]
  2. Shi S, Wu J, Chen H, Chen H, Wu J, Zeng F: Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol. 2007 Oct;47(10):1268-76. [PubMed:17906160]
External Links
PubChem Compound
40632
PubChem Substance
175426915
ChemSpider
37115
BindingDB
50005201
ChEBI
32016
ChEMBL
CHEMBL1256391
ATC Codes
L04AX05 — Pirfenidone
AHFS Codes
  • 48:02.00 — Antifibrotic Agents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedPreventionNeurofibromatosis Type 1 / Precancerous Conditions1
1CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
1RecruitingTreatmentCancer, Advanced / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Metastatic Lung Cancer / Non-Squamous Non-Small Cell Neoplasm of Lung / Squamous Cell Carcinoma of Lung1
1, 2CompletedTreatmentChronic Kidney Disease (CKD) / Fibrosis1
1, 2CompletedTreatmentDiabetes Mellitus (DM) / Diabetic Nephropathies1
2Active Not RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
2CompletedNot AvailableIdiopathic Pulmonary Fibrosis (IPF) / Pulmonary Fibrosis1
2CompletedTreatmentAlbinism / Albinism, Oculocutaneous / Inborn Errors of Metabolism / Platelet Storage Pool Deficiency / Pulmonary Fibrosis1
2CompletedTreatmentFibrosis / Glomerulonephritis minimal lesion / Glomerulosclerosis, Focal Segmental / Proteinuria / Renal Failure1
2CompletedTreatmentFibrosis / Hepatitis C Chronic1
2CompletedTreatmentHypertrophic Cardiomyopathy1
2CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)2
2CompletedTreatmentLeiomyomas / Uterine Leiomyomas1
2CompletedTreatmentNeurofibromatosis1
2CompletedTreatmentNeurofibromatosis 1 / Plexiform Neurofibroma1
2CompletedTreatmentSclerosis, Progressive Systemic1
2Not Yet RecruitingTreatmentGraft Versus Host Disease (GVHD) / Obliterative Bronchiolitis1
2Not Yet RecruitingTreatmentInterstitial Lung Disease (ILD) / Scleroderma, Systemic1
2RecruitingTreatmentCardiac Failure1
2RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
2RecruitingTreatmentLung Diseases, Interstitial1
2RecruitingTreatmentRheumatoid Arthritis Interstitial Lung Disease1
2Unknown StatusTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
2Unknown StatusTreatmentRadiation Pneumonitis1
2, 3Not Yet RecruitingTreatmentSclerosis, Progressive Systemic1
2, 3RecruitingTreatmentCLAD, Bronchiolitis Obliterans / Disorders Related to Lung Transplantation / Obliterative Bronchiolitis1
2, 3RecruitingTreatmentExtrinsic Allergic Alveolitis / Pulmonary Fibrosis1
3CompletedTreatmentDiabetic Foot Ulcers (DFU)1
3CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)4
3RecruitingTreatmentAlbuminuria / Diabetic Nephropathies1
3RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
3RecruitingTreatmentKeloid Scars1
4CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)3
4Not Yet RecruitingTreatmentAcute Kidney Injury (AKI) / Sepsis1
4Not Yet RecruitingTreatmentDermatopolymyositis / Interstitial Lung Disease (ILD)1
4RecruitingTreatmentSarcoidosis, Pulmonary1
Not AvailableApproved for MarketingNot AvailableIdiopathic Pulmonary Fibrosis (IPF)1
Not AvailableCompletedNot AvailableIdiopathic Pulmonary Fibrosis (IPF)2
Not AvailableCompletedSupportive CareRadiation Fibrosis1
Not AvailableRecruitingNot AvailableIdiopathic Pulmonary Fibrosis (IPF)1
Not AvailableRecruitingNot AvailablePulmonary Fibrosis1
Not AvailableRecruitingTreatmentInterstitial Lung Disease (ILD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral267 mg/1
CapsuleOral267 mg
TabletOral267 mg
TabletOral801 mg
Tablet, coatedOral267 mg/1
Tablet, coatedOral801 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7988994No2006-09-222026-09-22Us
US7816383No2010-01-082030-01-08Us
US8013002No2010-01-082030-01-08Us
US8084475No2010-01-082030-01-08Us
US8778947No2013-08-302033-08-30Us
US7566729No2009-04-222029-04-22Us
US7767225No2006-09-222026-09-22Us
US7635707No2009-04-222029-04-22Us
US7767700No2007-12-182027-12-18Us
US8592462No2009-04-222029-04-22Us
US8383150No2006-09-222026-09-22Us
US8318780No2010-01-082030-01-08Us
US8420674No2007-12-182027-12-18Us
US7910610No2010-01-082030-01-08Us
US8648098No2010-01-082030-01-08Us
US8754109No2010-01-082030-01-08Us
US8609701No2009-04-222029-04-22Us
US8753679No2006-09-222026-09-22Us
US7696236No2007-12-182027-12-18Us
US9561217No2002-01-252022-01-25Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.89 mg/mLALOGPS
logP2ALOGPS
logP2.14ChemAxon
logS-1.8ALOGPS
pKa (Strongest Basic)-1.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area20.31 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity57 m3·mol-1ChemAxon
Polarizability20.28 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9932
Blood Brain Barrier+0.996
Caco-2 permeable+0.8614
P-glycoprotein substrateNon-substrate0.8193
P-glycoprotein inhibitor INon-inhibitor0.755
P-glycoprotein inhibitor IINon-inhibitor0.9177
Renal organic cation transporterNon-inhibitor0.8157
CYP450 2C9 substrateNon-substrate0.6638
CYP450 2D6 substrateNon-substrate0.8248
CYP450 3A4 substrateSubstrate0.6111
CYP450 1A2 substrateInhibitor0.9108
CYP450 2C9 inhibitorNon-inhibitor0.5982
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.7166
CYP450 3A4 inhibitorNon-inhibitor0.775
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7633
Ames testNon AMES toxic0.7652
CarcinogenicityNon-carcinogens0.8992
BiodegradationNot ready biodegradable0.9112
Rat acute toxicity2.1330 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9784
hERG inhibition (predictor II)Non-inhibitor0.6301
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-2900000000-b9809376eba9769e9bee

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyridinones. These are compounds containing a pyridine ring, which bears a ketone.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Pyridinones
Alternative Parents
Methylpyridines / Dihydropyridines / Benzene and substituted derivatives / Heteroaromatic compounds / Lactams / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides
show 1 more
Substituents
Dihydropyridine / Pyridinone / Methylpyridine / Monocyclic benzene moiety / Benzenoid / Heteroaromatic compound / Lactam / Azacycle / Organic nitrogen compound / Hydrocarbon derivative
show 6 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
ring assembly, pyridone (CHEBI:32016)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Furin is likely to represent the ubiquitous endoprotease activity within constitutive secretory pathways and capable of cleavage at the RX(K/R)R consensus motif.
Gene Name
FURIN
Uniprot ID
P09958
Uniprot Name
Furin
Molecular Weight
86677.375 Da
References
  1. Burghardt I, Tritschler F, Opitz CA, Frank B, Weller M, Wick W: Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun. 2007 Mar 9;354(2):542-7. Epub 2007 Jan 10. [PubMed:17234158]

Drug created on October 21, 2007 16:23 / Updated on November 22, 2017 12:36